Rationale and design of three observational, prospective cohort studies including biobanking to evaluate and improve diagnostics, management strategies and risk stratification in venous thromboembolism: The VTEval Project

BMJ Open

Volumn 5, Issue 7, 2015, Pages

  Frank, Bernd ^a   Ariza, Liana ^a   Lamparter, Heidrun ^a   Grossmann, Vera ^a   Prochaska, Jürgen H ^a   Ullmann, Alexander ^a   Kindler, Florentina ^a   Weisser, Gerhard ^a   Walter, Ulrich ^a   Lackner, Karl J ^a   Espinola Klein, Christine ^a   Münzel, Thomas ^a,b   Konstantinides, Stavros V ^a   Wild, Philipp S ^a,b  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE DISEASE; ARTICLE; COHORT ANALYSIS; DEEP VEIN THROMBOSIS; FOLLOW UP; HUMAN; LUNG EMBOLISM; MORTALITY; OBSERVATIONAL STUDY; PROGNOSIS; PROSPECTIVE STUDY; RISK ASSESSMENT; STUDY DESIGN; VENOUS THROMBOEMBOLISM; BIOBANK; FEMALE; LIFESTYLE; MALE; METHODOLOGY; PSYCHOLOGY; PULMONARY EMBOLISM; RISK FACTOR; TREATMENT OUTCOME; VENOUS THROMBOSIS;

BIOLOGICAL MARKER;

BIOLOGICAL SPECIMEN BANKS; BIOMARKERS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIFE STYLE; MALE; PROSPECTIVE STUDIES; PULMONARY EMBOLISM; RESEARCH DESIGN; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 84937210430     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2015-008157     Document Type: Article

References (71)

1. Cohen AT, Agnelli G, Anderson F.A., et al. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost 2007; 98:756-64.
2. Go AS, Mozaffarian D, Roger V.L., et al. Heart disease and stroke statistics - 2014 update: a report from the American Heart Association. Circulation 2014; 129:e28-92.
3. Silverstein MD, Heit JA, Mohr D.N., et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 1998; 158:585-93.
4. White RH. The epidemiology of venous thromboembolism. Circulation 2003; 107(23 Suppl 1):I4-8.
5. Pengo V, Lensing AW, Prins M.H., et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 2004; 350:2257-64.
6. Lefebvre P, Laliberte F, Nutescu E.A., et al. All-cause and potentially disease-related health care costs associated with venous thromboembolism in commercial, Medicare, and Medicaid beneficiaries. J Manag Care Pharm 2012; 18:363-74.
7. Siccama RN, Janssen KJ, Verheijden N.A., et al. Systematic review: diagnostic accuracy of clinical decision rules for venous thromboembolism in elderly. Ageing Res Rev 2011; 10:304-13.
8. Wells PS, Forgie MA, Rodger MA Treatment of venous thromboembolism. JAMA 2014; 311:717-28.
9. Wells PS, Anderson DR, Bormanis J, et al Value of assessment of pretest probability of deep-vein thrombosis in clinical management. Lancet 1997; 350:1795-8.
10. Wells PS, Anderson DR, Rodger M, et al Derivation of a simple clinical model to categorize patients probability of pulmonary embolism: increasing the models utility with the SimpliRED D-dimer. Thromb Haemost 2000; 83:416-20.
11. Velagaleti RS, Gona P, Chuang M.L., et al. Relations of insulin resistance and glycemic abnormalities to cardiovascular magnetic resonance measures of cardiac structure and function: the Framingham Heart Study. Circ Cardiovasc Imaging 2010; 3:257-63.
12. Koenig W, Karakas M, Zierer A., et al. Oxidized LDL and the risk of coronary heart disease: results from the MONICA/KORA Augsburg Study. Clin Chem 2011; 57:1196-200.
13. Alte D, Ludemann J, Piek M., et al. Distribution and dose response of laboratory markers to alcohol consumption in a general population: results of the study of health in Pomerania (SHIP). J Stud Alcohol 2003; 64:75-82.
14. Wild PS, Zeller T, Beutel M., et al. The Gutenberg health study. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2012; 55:824-9.
15. Grande G, Jordan J, Kummel M., et al. Evaluation of the German Type D Scale (DS14) and prevalence of the Type D personality pattern in cardiological and psychosomatic patients and healthy subjects. Psychother Psychosom Med Psychol 2004; 54:413-22.
16. Denollet J. Personality and coronary heart disease: the type-D scale-16 (DS16). Ann Behav Med 1998; 20:209-15.
17. Kroenke K, Spitzer RL, Williams J.B., et al. Anxiety disorders in primary care: prevalence, impairment, comorbidity, and detection. Ann Intern Med 2007; 146:317-25.
18. Kroenke K, Spitzer RL, Williams JB The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 2001; 16:606-13.
19. Connor KM, Kobak KA, Churchill L.E., et al. Mini-SPIN: a brief screening assessment for generalized social anxiety disorder. Depress Anxiety 2001; 14:137-40.
20. Kroenke K, Spitzer RL, Williams JB The PHQ-15: validity of a new measure for evaluating the severity of somatic symptoms. Psychosom Med 2002; 64:258-66.
21. Michal M, Zwerenz R, Tschan R., et al. Screening for depersonalization-derealization with two items of the Cambridge depersonalization scale. Psychother Psychosom Med Psychol 2010; 60:175-9.
22. Wendel-Vos G.C., Schuit AJ, Saris W.H., et al. Reproducibility and relative validity of the short questionnaire to assess health-enhancing physical activity. J Clin Epidemiol 2003; 56:1163-9.
23. Klok FA, Cohn DM, Middeldorp S, et al Quality of life after pulmonary embolism: validation of the PEmb-QoL Questionnaire. J Thromb Haemost 2010; 8:523-32.
24. Cano SJ, Lamping DL, Bamber L, et al The Anti-Clot Treatment Scale (ACTS) in clinical trials: cross-cultural validation in venous thromboembolism patients. Health Qual Life Outcomes 2012; 10:120.
25. Martinez C, Cohen AT, Bamber L, et al Epidemiology of first and recurrent venous thromboembolism: a population-based cohort study in patients without active cancer. Thromb Haemost 2014; 112:255-63.
26. Bittar LF, Mazetto BM, Orsi F.L., et al. Long-term increased factor VIII levels are associated to interleukin-6 levels but not to post-thrombotic syndrome in patients with deep venous thrombosis. Thromb Res 2015; 135:497-501.
27. Ghozlan MF, Osman AA, Mahmoud H.M., et al. Comprehensive study on laboratory biomarkers for prediction and diagnosis of deep venous thrombosis. Blood Coagul Fibrinolysis 2015; 26:255-60.
28. Zacho J, Tybjaerg-Hansen A, Nordestgaard BG. C-reactive protein and risk of venous thromboembolism in the general population. Arterioscler Thromb Vasc Biol 2010; 30:1672-8.
29. Folsom AR, Lutsey PL, Astor B.C., et al. C-reactive protein and venous thromboembolism. A prospective investigation in the ARIC cohort. Thromb Haemostasis 2009; 102:615-19.
30. Magenta A, Greco S, Gaetano C., et al. Oxidative stress and microRNAs in vascular diseases. Int J Mol Sci 2013; 14:17319-46.
31. Magenta A, Cencioni C, Fasanaro P., et al. miR-200c is upregulated by oxidative stress and induces endothelial cell apoptosis and senescence via ZEB1 inhibition. Cell Death Differ 2011; 18:1628-39.
32. Hao L, Wang XG, Cheng J.D., et al. The up-regulation of endothelin-1 and down-regulation of miRNA-125a-5p, -155, and -199a/b-3p in human atherosclerotic coronary artery. Cardiovasc Pathol 2014; 23:217-23.
33. Reddy MA, Jin W, Villeneuve L., et al. Pro-inflammatory role of microrna-200 in vascular smooth muscle cells from diabetic mice. Arterioscler Thromb Vasc Biol 2012; 32:721-9.
34. Ramacciotti E, Blackburn S, Hawley A.E., et al. Evaluation of soluble P-selectin as a marker for the diagnosis of deep venous thrombosis. Clin Appl Thromb Hemost 2011; 17:425-31.
35. Vandy FC, Stabler C, Eliassen A.M., et al. Soluble P-selectin for the diagnosis of lower extremity deep venous thrombosis. J Vasc Surg Venous Lymphat Disord 2013; 1:117-25.
36. Rabinovich A, Cohen JM, Cushman M, et al Inflammation markers and their trajectories after deep vein thrombosis in relation to risk of postthrombotic syndrome. J Thromb Haemost 2015; 13:398-408.
37. Prochaska JH, Coldewey M, Gobel S., et al. Evaluation of oral anticoagulation therapy: rationale and design of the thrombEVAL study programme. Eur J Prev Cardiol 2015; 22:622-8.
38. Schellong SM. Diagnosis of recurrent deep vein thrombosis. Hamostaseologie 2013; 33:195-200.
39. Hou H, Ge Z, Ying P., et al. Biomarkers of deep venous thrombosis. J Thromb Thrombolysis 2012; 34:335-46.
40. Konstantinides S, Torbicki A. Management of venous thrombo-embolism: an update. Eur Heart J 2014; 35:2855-63.
41. Konstantinides SV, Torbicki A, Agnelli G., et al., Authors/Task Force M. 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC) Endorsed by the European Respiratory Society (ERS). Eur Heart J 2014; 35:3033-69.
42. Goodacre S, Sampson FC, Sutton A.J., et al. Variation in the diagnostic performance of D-dimer for suspected deep vein thrombosis. QJM 2005; 98:513-27.
43. Sartori M, Cosmi B, Legnani C., et al. The Wells rule and D-dimer for the diagnosis of isolated distal deep vein thrombosis. J Thromb Haemost 2012; 10:2264-9.
44. Luxembourg B, Schwonberg J, Hecking C., et al. Performance of five D-dimer assays for the exclusion of symptomatic distal leg vein thrombosis. Thromb Haemost 2012; 107:369-78.
45. Xu J, Zhao J, Evan G., et al. Circulating microRNAs: novel biomarkers for cardiovascular diseases. J Mol Med 2012; 90:865-75.
46. Xu J, Lupu F, Esmon CT Inflammation, innate immunity and blood coagulation. Hamostaseologie 2010; 30:5-6, 8-9.
47. Morange PE, Tregouet DA Lessons from genome-wide association studies in venous thrombosis. J Thromb Haemost 2011; 9(suppl 1):258-64.
48. Zoller B, Li X, Sundquist J., et al. Familial transmission of venous thromboembolism: a cohort study of 80 214 Swedish adoptees linked to their biological and adoptive parents. Circ Cardiovasc Genet 2014; 7:296-303.
49. Mannhalter C. Biomarkers for arterial and venous thrombotic disorders. Hamostaseologie 2014; 34:115-20, 22-6, 28-30, passim.
50. Ramacciotti E, Hawley AE, Wrobleski S.K., et al. Proteomics of microparticles after deep venous thrombosis. Thromb Res 2010; 125: e269-74.
51. Bucek RA, Reiter M, Quehenberger P., et al. C-reactive protein in the diagnosis of deep vein thrombosis. Br J Haematol 2002; 119:385-9.
52. Cohen AT, Imfeld S, Rider T. Phase III trials of new oral anticoagulants in the acute treatment and secondary prevention of VTE: comparison and critique of study methodology and results. Adv Ther 2014; 31:473-93.
53. Kearon C, Akl EA Duration of anticoagulant therapy for deep vein thrombosis and pulmonary embolism. Blood 2014; 123:1794-801.
54. Ghanny S, Crowther M. Treatment with novel oral anticoagulants: indications, efficacy and risks. Curr Opin Hematol 2013; 20:430-6.
55. Kearon C, Akl EA, Comerota A.J., et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141(2 Suppl):e419S-94S.
56. Thavarajah D, Wetherill M. Implementing NICE guidelines on risk assessment for venous thromboembolism: failure, success and controversy. Int J Health Care Qual Assur 2012; 25:618-24.
57. Investigators E, Bauersachs R, Berkowitz S.D., et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363:2499-510.
58. Agnelli G, Buller HR, Cohen A, et al Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013; 369:799-808.
59. Raskob G, Buller H, Prins M., et al. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study-methodological implications for clinical trials. J Thromb Haemost 2013; 11:1287-94.
60. Schulman S, Kakkar AK, Goldhaber S.Z., et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation 2014; 129:764-72.
61. Lozano F, Trujillo-Santos J, Barron M., et al. Home versus in-hospital treatment of outpatients with acute deep venous thrombosis of the lower limbs. J Vasc Surg 2014; 59:1362-7 e1.
62. Zondag W, Mos IC, Creemers-Schild D, et al. Outpatient treatment in patients with acute pulmonary embolism: the Hestia Study. J Thromb Haemost 2011; 9:1500-7.
63. Bates SM, Jaeschke R, Stevens S.M., et al. Diagnosis of DVT: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141(2 Suppl):e351S-418S.
64. Rodger MA, Kahn SR, Wells P.S., et al. Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. CMAJ 2008; 179:417-26.
65. Caldeira D, Barra M, Pinto F.J., et al. Intracranial hemorrhage risk with the new oral anticoagulants: a systematic review and meta-analysis. J Neurol 2015; 262:516-22.
66. Wells P, Anderson D. The diagnosis and treatment of venous thromboembolism. Hematology Am Soc Hematol Educ Program 2013; 2013:457-63.
67. Poli D, Palareti G. Assessing recurrence risk following acute venous thromboembolism: use of algorithms. Curr Opin Pulm Med 2013; 19:407-12.
68. Prandoni P. Anticoagulant treatment of pulmonary embolism: impact and implications of the EINSTEIN PE study. Eur J Haematol 2012; 89:281-7.
69. Ozsu S, Cinarka H. Chronic thromboembolic pulmonary hypertension: Medical treatment. Pulm Circ 2013; 3:341-4.
70. Guerin L, Couturaud F, Parent F., et al. Prevalence of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism. Prevalence of CTEPH after pulmonary embolism. Thromb Haemost 2014; 112:598-605.
71. Kim NH, Delcroix M, Jenkins D.P., et al. Chronic thromboembolic pulmonary hypertension. J Am Coll Cardiol 2013; 62(25 Suppl):D92-9.